{"product_id":"vtyx-vrio-analysis","title":"Ventyx Biosciences, Inc. (VTYX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Ventyx Biosciences, Inc. (VTYX)'s competitive edge starts here: our focused VRIO analysis cuts straight to the core, examining the Value, Rarity, Inimitability, and Organization of its key assets. The distilled summary of \u0026amp;O4\u0026amp; reveals precisely where sustainable advantage lies - or where critical gaps exist. Scroll down immediately to grasp the strategic implications and find out if Ventyx Biosciences, Inc. (VTYX) is truly built to last.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 1: Proprietary NLRP3 Inhibitor Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at Ventyx Biosciences, Inc.'s core strength: its dual-pronged approach to targeting the NLRP3 inflammasome, which is implicated in a host of chronic diseases. This platform, featuring two distinct oral candidates, is what separates them in a crowded field. The entire market for NLRP3 Inhibitors, which stood at about \u003cstrong\u003e$1.16 billion\u003c\/strong\u003e globally in 2024, is projected to grow rapidly, potentially reaching over \u003cstrong\u003e$10 billion\u003c\/strong\u003e by 2033, though your total addressable market across all potential indications is estimated to be well over \u003cstrong\u003e$100 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Best-in-Class Oral Potential\u003c\/h3\u003e\n\u003cp\u003eThe platform is valuable because it offers potential best-in-class oral therapies for systemic inflammation. You have VTX2735, which is peripherally restricted, and VTX3232, which is CNS-penetrant. This dual targeting addresses different disease compartments, which is a huge plus. For instance, VTX3232 already showed compelling data in obesity and cardiometabolic risk factors, with key takeaways from the Phase 2 study showing high-sensitivity C-reactive protein (hsCRP) levels reduced by nearly \u003cstrong\u003e80%\u003c\/strong\u003e. That’s a concrete measure of anti-inflammatory power. The company’s financial footing also supports this value proposition, as their cash, cash equivalents, and marketable securities totaled \u003cstrong\u003e$192.6 million\u003c\/strong\u003e as of September 30, 2025, expected to fund operations into at least the second half of 2026.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Two Advanced, Distinct Candidates\u003c\/h3\u003e\n\u003cp\u003eWhile the NLRP3 target is certainly hot right now, having two distinct, advanced candidates in Phase 2 trials simultaneously is relatively rare for a company of Ventyx Biosciences’ size. VTX3232 has demonstrated CNS penetration, hitting targets in the cerebrospinal fluid (CSF) exceeding the IC90 for NLRP3 inhibition by over \u003cstrong\u003e3-fold\u003c\/strong\u003e in early Parkinson's disease studies. VTX2735, on the other hand, is focused on peripheral indications like recurrent pericarditis. This breadth of specialized candidates makes the platform rare. It’s not just one shot on goal; it’s a targeted arsenal. \u003c\/p\u003e\n\n\u003ch3\u003eImitability: Strong Intellectual Property Moat\u003c\/h3\u003e\n\u003cp\u003eImitation is difficult here, honestly. The specific chemical structures for both VTX2735 and VTX3232, along with the associated preclinical and clinical data packages, are protected by intellectual property rights. Direct imitation would require designing around existing patents and replicating years of specialized medicinal chemistry and biology work. That takes significant time and capital, which acts as a barrier. The specific data showing VTX3232 achieving steady-state concentrations in CSF exceeding the IC90 for 24 hours is hard to replicate without knowing the exact molecule.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Executing Against Milestones\u003c\/h3\u003e\n\u003cp\u003eThe organization appears strong, evidenced by its ability to advance both lead candidates into multiple Phase 2 trials concurrently and deliver on key timelines. They successfully reported topline data for VTX3232 in early Parkinson's disease in June 2025 and for obesity in October 2025. Management is now focused on the final major milestone for 2025: reporting topline data from the Phase 2 trial of VTX2735 in recurrent pericarditis in the fourth quarter. Their ability to manage R\u0026amp;D expenses, which decreased to \u003cstrong\u003e$22.9 million\u003c\/strong\u003e in Q1 2025 from $33.7 million the prior year, while still advancing the pipeline, shows disciplined resource allocation.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Evaluation\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage here is \u003cstrong\u003eSustained\u003c\/strong\u003e, but it hinges entirely on the upcoming data. If the Q4 2025 data for VTX2735 in recurrent pericarditis is positive - showing efficacy on pain scores and hsCRP - and aligns with the strong biomarker engagement seen with VTX3232, Ventyx Biosciences will have validated two distinct, best-in-class oral agents in high-value areas. That validation translates directly into a sustained advantage until a competitor can prove superior efficacy or safety in those specific indications. \u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this core capability:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eAddresses large, high-unmet-need markets (e.g., obesity, pericarditis).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTwo distinct, advanced-stage, CNS-penetrant and peripherally restricted candidates.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eProtected by specific intellectual property and complex development history.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSuccessfully advancing multiple Phase 2 trials concurrently; managing cash burn effectively.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained (Contingent)\u003c\/td\u003e\n\u003ctd\u003eAdvantage is sustained if Q4 2025 VTX2735 data is positive.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the competitive landscape; other players like Ventus Therapeutics and Olatec Therapeutics are also advancing NLRP3 inhibitors, so speed to market and data quality are paramount.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 2: CNS-Penetrant VTX3232 Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 2: CNS-Penetrant VTX3232 Asset\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eUnlocks the high-value neurodegenerative disease space, like Parkinson's, by demonstrating high drug exposure in the cerebrospinal fluid (CSF) and potent biomarker suppression.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSF Concentration (24h post-dose)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30.4 ng\/mL\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 2a Trial (PD Patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIC90 for NLRP3 Inhibition\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e9 ng\/mL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIn vitro threshold\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSF Exposure vs. IC90\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;3-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt steady state\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIL-1$\\beta$ \u0026amp; IL-18 Reduction (28 days)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14% to 52%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn Plasma and CSF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDownstream Biomarker Reduction (28 days)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29% to 70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIL-6, CRP, SAA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2a Trial Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Period\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOpen-label trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eRare. Achieving therapeutic CSF exposure with an oral small molecule for a CNS target is a significant hurdle cleared by VTX3232.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 trial showed CSF exposures completely blocked IL-1$\\beta$ at 10 to 15 milligrams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. Competitors are trying, but Ventyx Biosciences has already generated positive Phase 2a biomarker data here.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePositive top-line data from Phase 2a trial announced in June 2025.\u003c\/li\u003e\n\u003cli\u003eThe trial met its primary safety and tolerability objectives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eExcellent organization to exploit this, as the CEO specifically highlighted the transformative nature of this data in 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitiated planning discussions for a placebo-controlled Phase 2 trial in Parkinson's disease and potentially in Alzheimer's disease.\u003c\/li\u003e\n\u003cli\u003eVentyx is seeking partners to explore combination therapies and enhance VTX3232 development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. It’s a first-mover advantage in this specific molecule\/target combination, but success will draw immediate, well-funded competition.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Capitalization as of June 17, 2025: \u003cstrong\u003e$181 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of June 30, 2025: \u003cstrong\u003e$209.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 3: Selective TYK2 Inhibitor (VTX958)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 3: Selective TYK2 Inhibitor (VTX958)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\nValue: Provides a differentiated asset for inflammatory bowel disease (IBD) that avoids the broader JAK inhibition toxicities, potentially offering a better safety profile than existing options.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 trial demonstrated VTX958 was well tolerated across all cohorts with no drug-related serious adverse events (SAEs) reported.\u003c\/li\u003e\n\u003cli\u003ePhase 1 data showed no significant effects on hematological parameters, lipids\/triglycerides, and CPK laboratory values.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nRarity: Moderate. Other selective TYK2 inhibitors exist, but VTX958 has already completed Phase 2 trials, giving it a head start in data generation.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 achieved TYK2 IC50 and IC90 coverage up to 24 hours.\u003c\/li\u003e\n\u003cli\u003eThe Phase 2 Crohn's disease trial randomized 109 participants to one of two VTX958 doses or placebo for a 12-week induction treatment period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEndpoint Measure\u003c\/th\u003e\n\u003cth\u003eVTX958 Result vs. Placebo\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint (Change in CDAI)\u003c\/td\u003e\n\u003ctd\u003eDid not meet primary endpoint.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecondary Endpoint (Endoscopic Response - SES-CD)\u003c\/td\u003e\n\u003ctd\u003eBoth doses reached nominal statistical significance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker (C-reactive protein \u0026amp; Fecal Calprotectin)\u003c\/td\u003e\n\u003ctd\u003eShowed greater magnitude of reduction compared to placebo.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nImitability: Moderate. The selectivity profile is a result of specific medicinal chemistry work, which is hard to copy exactly.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVTX958 is an oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2).\u003c\/li\u003e\n\u003cli\u003eTYK2 regulates IFN$\\alpha$, IL-12, and IL-23 signaling.\u003c\/li\u003e\n\u003cli\u003ePhase 1 confirmed robust dose-dependent pharmacodynamic activity via in vivo IFN$\\alpha$ challenge and ex vivo IL-12\/IL-18 stimulation assays.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nOrganization: The company has shown it can progress this asset through Phase 2, but current focus seems to be on partnerships for this portfolio.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of June 30, 2025, cash, cash equivalents, and marketable securities totaled $209.0 million.\u003c\/li\u003e\n\u003cli\u003eCash position is believed to be sufficient to fund planned operations into at least H2 2026.\u003c\/li\u003e\n\u003cli\u003eThe company is exploring multiple options for continued development of VTX958, including partnership opportunities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary. The asset is valuable, but the need to explore partnerships suggests they may not have the resources for a full-scale commercial launch alone.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVTX958 previously had development terminated in plaque psoriasis after the 'magnitude of efficacy' fell short of internal targets, despite meeting primary and key secondary endpoints.\u003c\/li\u003e\n\u003cli\u003eThe company does not anticipate conducting additional clinical trials of VTX958 with internal resources following the Crohn's Phase 2 results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 4: Financial Runway and Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: The cash balance provides the necessary time to execute on critical, value-defining clinical readouts without immediate dilution pressure.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Moderate. A cash position of \u003cstrong\u003e$192.6 million\u003c\/strong\u003e as of September 30, 2025, funding operations into at least \u003cstrong\u003eH2 2026\u003c\/strong\u003e, is solid for a clinical-stage firm.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Low. Cash is fungible; it’s a resource, not a unique skill.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Good. Management is actively managing burn, reflected in expense reductions and the resulting narrowed net loss of \u003cstrong\u003e$22.8 million\u003c\/strong\u003e in Q3 2025, compared to \u003cstrong\u003e$35.2 million\u003c\/strong\u003e in Q3 2024.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nR\u0026amp;D expenses were \u003cstrong\u003e$17.7 million\u003c\/strong\u003e for the third quarter of 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nG\u0026amp;A expenses were \u003cstrong\u003e$7.2 million\u003c\/strong\u003e for the third quarter of 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nNet loss for Q3 2025 was \u003cstrong\u003e$22.8 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative (G\u0026amp;A) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary. This runway is a clock; it buys time until the next data point, but it is finite.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 5: Deep Small Molecule Drug Discovery Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 5: Deep Small Molecule Drug Discovery Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: The foundational ability to design and optimize novel, differentiated small molecule therapeutics for complex targets like NLRP3 and TYK2.\u003c\/p\u003e\n\u003cp\u003eRarity: High. Expertise spanning medicinal chemistry, structural biology, and immunology is the engine that created the current pipeline.\u003c\/p\u003e\n\u003cp\u003eImitability: High. This is tacit knowledge embedded in the team, not easily replicated by hiring a few new scientists.\u003c\/p\u003e\n\u003cp\u003eOrganization: Strong. This expertise is clearly reflected in the portfolio's focus on oral bioavailability and target selectivity.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained. This core scientific skill set is what allows Ventyx Biosciences to generate new pipeline assets.\u003c\/p\u003e\n\u003cp\u003eThe depth of this expertise is evidenced by the clinical progression and target engagement data achieved by internally discovered assets:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecule\u003c\/th\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eKey Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX3232\u003c\/td\u003e\n\u003ctd\u003eNLRP3 (CNS-penetrant)\u003c\/td\u003e\n\u003ctd\u003eParkinson's Disease (Phase 2a)\u003c\/td\u003e\n\u003ctd\u003eCSF\/plasma concentrations exceeded IC\u003csub\u003e90\u003c\/sub\u003e for NLRP3 inhibition by ≥3-fold for 24-hours post-once-daily dose.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX3232\u003c\/td\u003e\n\u003ctd\u003eNLRP3 (CNS-penetrant)\u003c\/td\u003e\n\u003ctd\u003eObesity\/CV Risk (Phase 2)\u003c\/td\u003e\n\u003ctd\u003eAchieved nearly 80% reduction in hsCRP over 12-week study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX2735\u003c\/td\u003e\n\u003ctd\u003eNLRP3 (Peripherally restricted)\u003c\/td\u003e\n\u003ctd\u003eRecurrent Pericarditis (Phase 2)\u003c\/td\u003e\n\u003ctd\u003eTrial involved 30-patient, 6-week primary treatment period; topline data expected Q4 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX958\u003c\/td\u003e\n\u003ctd\u003eTYK2\u003c\/td\u003e\n\u003ctd\u003eCrohn's Disease (Phase 2)\u003c\/td\u003e\n\u003ctd\u003eDemonstrated robust endoscopic response at Week 12 and greater magnitude of reduction vs. placebo in fecal calprotectin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe successful demonstration of potent target engagement and biomarker modulation across multiple indications validates the discovery platform:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVTX3232 showed robust reductions in downstream biomarkers including IL-1β, IL-6, and hsCRP in both plasma and CSF in Parkinson's patients.\u003c\/li\u003e\n\u003cli\u003eVTX3232 also demonstrated significant reductions in Lp(a) in the obesity\/cardiovascular risk factor study.\u003c\/li\u003e\n\u003cli\u003eThe company's cash position as of Third Quarter 2025 was $192.6M, supporting continued R\u0026amp;D execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 6: Experienced Clinical Development Leadership\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eAllows for the rapid progression of drug candidates through complex clinical trials, as seen by having three major Phase 2 studies underway or recently completed in 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2 biomarker trial of VTX3232 in Parkinson's disease on track to complete in Q2 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 2 trial of VTX2735 in recurrent pericarditis with topline data expected in H2 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 2 trial of VTX3232 in obesity and cardiometabolic risk factors with topline data expected in H2 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 2 data for VTX958 in Crohn's disease presented at the 20th Congress of the European Crohn's and Colitis Organisation (February 2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Many biotechs have clinical teams, but Ventyx Biosciences has successfully navigated multiple Phase 2 initiations and data readouts in a compressed timeframe.\u003c\/p\u003e\n\u003cp\u003eThe clinical leadership includes personnel with significant prior experience:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eRole\u003c\/td\u003e\n\u003ctd\u003eName\/Title Detail\u003c\/td\u003e\n\u003ctd\u003eExperience Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Medical Officer (CMO)\u003c\/td\u003e\n\u003ctd\u003eDr. Mark S. Forman, MD, PhD\u003c\/td\u003e\n\u003ctd\u003eNearly two decades of experience in translational research for neurological disorders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSVP, Clinical Development\u003c\/td\u003e\n\u003ctd\u003eSnehal Naik, PHD\u003c\/td\u003e\n\u003ctd\u003eSpecific tenure not detailed, but holds senior clinical development role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO Prior Role\u003c\/td\u003e\n\u003ctd\u003eDr. Mark S. Forman\u003c\/td\u003e\n\u003ctd\u003eChief Medical Officer at Passage Bio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate. While key personnel can be poached, the established processes and relationships are harder to copy.\u003c\/p\u003e\n\u003cp\u003eFinancial investment in clinical development:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for Q1 2025 were $22.9 million.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q2 2025 were $22.3 million.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q3 2025 were $17.7 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eMixed. The management team's average tenure is short at 1.5 years, which is a slight flag, but the clinical SVP and CMO have deep experience.\u003c\/p\u003e\n\u003cp\u003eManagement Tenure Snapshot:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage Management Tenure: 1.5 years.\u003c\/li\u003e\n\u003cli\u003eCEO Tenure (Raju Mohan): 7.08 years (appointed Nov 2018).\u003c\/li\u003e\n\u003cli\u003eCMO Appointment Date: August 12, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. Success depends heavily on retaining key clinical leaders like the Chief Medical Officer, Dr. Mark S. Forman.\u003c\/p\u003e\n\u003cp\u003eFinancial Runway Supporting Continued Clinical Execution:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDate\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003eFunding Outlook\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$252.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInto at least H2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$228.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInto at least H2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$209.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInto at least H2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$192.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInto at least H2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 7: Focused Pipeline Breadth (Multi-Target\/Multi-Indication)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Mitigates single-asset risk by having multiple shots on goal across inflammation (NLRP3, TYK2) and neurology (Parkinson's).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many clinical-stage companies are single-asset focused; Ventyx Biosciences has a portfolio of four distinct Phase 2 compounds.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Building a portfolio of this diversity takes years of R\u0026amp;D investment and strategic focus.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. The organization is structured to manage distinct therapeutic areas simultaneously, though it strains resources.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Diversification across targets and indications provides a buffer against clinical failure in any one area.\u003c\/p\u003e\n\n\u003cp\u003eThe focused pipeline breadth is evidenced by the simultaneous advancement of four distinct clinical programs:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompound\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003ctd\u003eIndication\/Focus Area\u003c\/td\u003e\n\u003ctd\u003eDevelopment Phase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX3232\u003c\/td\u003e\n\u003ctd\u003eNLRP3 (CNS-penetrant)\u003c\/td\u003e\n\u003ctd\u003eParkinson's disease\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX3232\u003c\/td\u003e\n\u003ctd\u003eNLRP3 (CNS-penetrant)\u003c\/td\u003e\n\u003ctd\u003eCardiometabolic diseases (Obesity\/Cardiovascular Risk Factors)\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX2735\u003c\/td\u003e\n\u003ctd\u003eNLRP3 (Peripheral)\u003c\/td\u003e\n\u003ctd\u003eRecurrent Pericarditis\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVTX958\u003c\/td\u003e\n\u003ctd\u003eTYK2\u003c\/td\u003e\n\u003ctd\u003eCrohn's disease\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTamuzimod (VTX002)\u003c\/td\u003e\n\u003ctd\u003eS1P1R\u003c\/td\u003e\n\u003ctd\u003eUlcerative Colitis\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinancial and operational metrics supporting the investment in this breadth include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of September 30, 2025, totaled \u003cstrong\u003e$192.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe current cash balance is believed sufficient to fund planned operations into at least \u003cstrong\u003eH2 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the third quarter of 2025 were \u003cstrong\u003e$17.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for the full year ended December 31, 2024, were \u003cstrong\u003e$117.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSanofi secured rights to VTX3232 in conjunction with a \u003cstrong\u003e$27 million\u003c\/strong\u003e investment in Ventyx.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSpecific Phase 2 trial details illustrating the multi-indication approach:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVTX3232 in Parkinson's disease (Phase 2a) evaluated a \u003cstrong\u003e40-mg\u003c\/strong\u003e oral daily dose over a \u003cstrong\u003e28-day\u003c\/strong\u003e treatment period in \u003cstrong\u003e10 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVTX3232 in Obesity\/Cardiometabolic Risk Factors Phase 2 trial enrolled approximately \u003cstrong\u003e160 subjects\u003c\/strong\u003e randomized to \u003cstrong\u003efour groups\u003c\/strong\u003e for a \u003cstrong\u003e12-week\u003c\/strong\u003e primary treatment period.\u003c\/li\u003e\n\u003cli\u003eData from the Obesity\/Cardiometabolic trial showed \u003cstrong\u003ehsCRP levels were reduced by nearly 80%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVTX958 in Crohn's disease Phase 2 demonstrated robust endoscopic response at \u003cstrong\u003eWeek 12\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 8: Established Corporate Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 8: Established Corporate Infrastructure\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eA functional base of operations in San Diego, CA, with established SEC reporting and corporate governance structures, which is essential for public trading.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow. Being based in a major biotech hub is common, but it’s a necessary foundation for operations.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow. Competitors can easily establish an office in San Diego, CA.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eAdequate. The company has the necessary compliance structure to operate as a public entity, despite having only \u003cstrong\u003e81\u003c\/strong\u003e total employees.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone. This is a necessary cost of doing business, not a source of advantage.\u003c\/p\u003e\n\u003cp\u003eThe company's infrastructure supports its status as a publicly traded entity on NASDAQ (Ticker VTYX) and its compliance requirements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCorporate Office Address: \u003cstrong\u003e12790 El Camino Real; Suite 200; San Diego, CA 92130\u003c\/strong\u003e, United States.\u003c\/li\u003e\n\u003cli\u003eTotal Employees: \u003cstrong\u003e81\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePublic Status: Publicly Held.\u003c\/li\u003e\n\u003cli\u003eSEC Filings include: Form 10-K, Form 10-Q, and Form 4.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eAs of Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$587M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e03-Nov-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71,358,638\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 3, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.94\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (Thousands USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e211,465\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM (30-Sep-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt (Thousands USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10,024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM (30-Sep-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company is subject to regular SEC disclosure requirements, as evidenced by filings such as the Form 4 filed on November 19, 2025, and the Form 10-Q filed on November 6, 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVentyx Biosciences, Inc. (VTYX) - VRIO Analysis: Core Capability 9: Leadership Vision and Focus\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Capability 9: Leadership Vision and Focus\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The clear, consistent focus on the NLRP3 inflammasome pathway, driven by the founder\/CEO, Dr. Raju Mohan, provides strategic clarity for investors and employees.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. A founder-led company with a clear scientific thesis (Dr. Raju Mohan) often maintains sharper focus than one led by a hired-in executive.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. The specific vision and conviction of the CEO, Dr. Raju Mohan, is not something a competitor can simply acquire.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong, as the CEO’s vision is driving the 2025 strategy and data communication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage relies on the current leadership remaining in place and maintaining that focus; if the CEO departs, this advantage erodes quickly.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday, incorporating the $192.6 million Q3 2025 cash balance.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Reported Amount\u003c\/td\u003e\n\u003ctd\u003eImplication for Cash View\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Equivalents, Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$192.6 million\u003c\/strong\u003e (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eFunds operations into at least \u003cstrong\u003eH2 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRepresents cash burn for the quarter (vs. $35.2 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInvestment supporting NLRP3 pipeline advancement (vs. $30.6 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOperational efficiency reflected (vs. $7.9 million in Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization's focus is evidenced by the planned data releases tied to the NLRP3 inhibitor portfolio in 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVTX3232 Parkinson's Disease Phase 2a data: Q2 2025 readout.\u003c\/li\u003e\n\u003cli\u003eVTX3232 Obesity and Cardiometabolic Risk Factors Phase 2 data: H2 2025 readout.\u003c\/li\u003e\n\u003cli\u003eVTX2735 Recurrent Pericarditis Phase 2 data: H2 2025 readout.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecific efficacy data supporting the focus on VTX3232:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReduction in hsCRP levels in obesity\/CV risk factors Phase 2 study: nearly \u003cstrong\u003e80%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVTX3232 CSF exposure in Parkinson's trial: Exceeding the IC\u003csub\u003e90\u003c\/sub\u003e for NLRP3 inhibition by ≥\u003cstrong\u003e3-fold\u003c\/strong\u003e for \u003cstrong\u003e24-hours\u003c\/strong\u003e post-dose (once-daily formulation).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516279054485,"sku":"vtyx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vtyx-vrio-analysis.png?v=1740228442","url":"https:\/\/dcf-model.com\/products\/vtyx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}